# Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

> **NCT00330330** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 96 (—)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** ISIS 113715

## Key facts

- **NCT ID:** NCT00330330
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 96 (—)
- **Last updated:** 2008-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00330330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00330330, "Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00330330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*